Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00909363 · ClinicalTrials.gov registry record · Phase 2
Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00909363 is a Phase 2 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 24 participants.
The verdict
NCT00909363, a Phase 2 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this project is to describe the pathophysiology of thrombocytopenia and bleeding in patients with Wiskott-Aldrich Syndrome (WAS) and determine the response to thrombopoietic agents in vitro and in vivo.
Interventions
- DRUG Promacta
- DIAGNOSTIC_TEST blood drawing in patients with WAS
- DIAGNOSTIC_TEST blood drawing in healthy controls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-06 |
| Est. Completion | 2017-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00909363
The ClinicalTrials.gov registry entry for NCT00909363 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Promacta is the first listed.
NCT00909363 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00909363 about?
NCT00909363 is a clinical study titled "Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients". The purpose of this project is to describe the pathophysiology of thrombocytopenia and bleeding in patients with Wiskott-Aldrich Syndrome (WAS) and determine the response to thrombopoietic agents in vitro and in vivo.
What is the current status of trial NCT00909363?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2009-06. Estimated completion is 2017-06-30.
What interventions are being tested in trial NCT00909363?
The interventions under investigation include: Promacta (DRUG), blood drawing in patients with WAS (DIAGNOSTIC_TEST), blood drawing in healthy controls (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT00909363?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.